Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adequate complete blood counts, liver and renal function.~* 12-lead electrocardiogram (ECG) within normal limits~* Female subjects must be of non-childbearing potential; e.g. post-menopausal or pre-menopausal with surgical sterilization~* Male subjects agree to use appropriate contraception~* Willing to provide written informed consent and willing to comply with study requirements~* Nonsmokers for at least 5 years before screening~Exclusion Criteria:~* Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk~* Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study~* Active serious mental illness or psychiatric disorder requiring current pharmacological intervention~* History or evidence of alcohol or drug abuse within 12 months before screening.~* History of intolerance to SC injection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ALN-AAT (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).